Invirsa closes $7.7 million Series B financing
Click Here to Manage Email Alerts
Key takeaways:
- Invirsa secured $7.7 million in financing.
- The funding will advance development of INV-102 for ocular conditions associated with DNA damage.
Invirsa closed $7.7 million in Series B financing earlier this year, according to a press release.
The financing was led by CincyTech, with Rev1 Ventures, JobsOhio Growth Capital Fund and JumpStart Ventures contributing.
The funds will be used to advance INV-102, the company’s lead product candidate, an eye drop for the treatment of ocular conditions associated with DNA damage; support phase 2 studies in acute infectious keratoconjunctivitis, dry eye disease and Fuchs’ corneal dystrophy; and prepare for phase 3 studies.
“The recent Series B funding is a significant milestone for Invirsa, which allows us to advance the clinical development of INV-102, a topical eye drop that has completed initial testing in dry eye patients (phases 1 and 2a),” Robert Shalwitz, MD, CEO of Invirsa, said in the release. “Dry eye continues to be an important market with a significant unmet medical need. The recent investment, led by CincyTech with other Ohio life science investment funds, provides strong validation of our vision and approach.”
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts